**Supplemental Materials for**

**Potent neutralizing humanized antibody with topical therapeutic potential against HPV18-related cervical cancer**

Bilian Huang 1†, Linjing Zhu 2†,Hongxia Wei3, Haixia Shi4, Doudou Zhang2, Huanyun Yuan2, Linlin Luan2, Nan Zheng1, Shijie Xu2, Waqas Nawaz1, Ying Hong5\*, Xilin Wu1,2\*, Zhiwei Wu 1, 6, 7, 8\*

*1.Center for Public Health Research, Medical School, Nanjing University, Nanjing, P.R. China.*

*2. Department of antibody, Abrev Biotechnology Co., Ltd. Nanjing, P.R. China.*

*3. Department of Infectious Disease, The second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, P.R. China.*

*4. Department of Antibody, Y-clone Medical science Co. Ltd. Suzhou, P.R. China.*

*5. Obstetrics and Gynecology Department, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China.*

*6. School of Life Sciences, Ningxia University, Yinchuan, P.R. China.*

*7. Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, P.R. China.*

*8. State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, P.R. China.*

\*Corresponding author: Z. Wu, E-mail: wzhw@nju.edu.cn, X. Wu, E-mail: xilinwu@nju.edu.cn Y. Hong, E-mail: hongying@nju.edu.cn.

Mailing address: School of Life Sciences, Ningxia University, Yinchuan, 750021, China. Phone: +86 (25) 8368-6092. Fax: +86 (25) 8359-6023.

†These authors contributed equally to this work.

**Supplemental figures**

****

**Supplemental Figure 1. VLPs binding to 2A12 and 8H4.** VLPs from various HPV types under reducing conditions (R) or nonreducing conditions (NR) was detected by western-blot with 2A12 (A) and 8H4 (B). Mouse polyclonal anti-sera specific (Anti-sera 1:10000 dilution) for HPV 18 VLP was taken as positive control.